NRSN:NASDAQ, NeuroSense Therapeutics Ltd.

Why NRSN stock fell on November 11

NeuroSense Therapeutics Ltd. fell 10.1% on Wednesday, November 11, 2026, on 51,900 shares. No headline about NRSN came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

NRSN stock overview

NeuroSense Therapeutics Ltd. (NRSN:NASDAQ) closed at $1.57 on November 16, 2026, down 7.40% on the day. The stock trades 93.8% below its 52-week high of $25.40 and 42.3% above its 52-week low of $1.10. Over the past year, it lost 93.7%. NeuroSense Therapeutics Ltd. is part of the Health Care sector.

Key figures

Price
$1.57
Day change
-7.40%
Volume
5,816
Average volume
32,593
Market cap
2M+
52-week range
$1.10 – $25.40
50-day average
$4.14
200-day average
$11.99

Price action over the past year

In 252 trading sessions since November 14, 2025, NRSN closed higher on 103 days (41%). Its best day was September 4, 2026 (+27.11%) and its worst was November 2, 2026 (-28.14%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

NRSN news

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Similar stocks

Find more stocks like NRSN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.